牛血清蛋白酶联免疫检测试剂盒的研制及验证

为研制酶联免疫试剂盒以检测病毒性疫苗中残余牛血清蛋白(BSP)含量,制备高效价高纯度的兔抗BSP多克隆抗体作为包被抗体和酶标抗体,建立了ELISA双抗体夹心法并组建试剂盒,通过标准剂量曲线可对样品中所含BSP、BSA及B-IgG进行定量,经验证该方法标准曲线线性范围内r≥0.98,对BSP的检测限量为3ng/ml;分别检测5、10、20ng/ml含量的BSP时,试验内(n=12)和试验间(n=3)测定的变异系数在3.71%到7.29%之间,回收率在93.4%~106.3%,未见该方法与人血清白蛋白、卵清蛋白以及疫苗复合保护剂之间有交叉反应。该法敏感度高,准确性、重复性和稳定性好,可用于疫苗牛血清残余蛋白的质量控制。     

牛血清蛋白酶联免疫试剂盒性能的验证

为了全面验证研制的牛血清蛋白(BSP)酶联免疫试剂盒的性能,由3个部门6人协作进行了验证。结果表明,,6人进行的18次试验全部满足BSP-ELISA试剂盒的质控标准,达标率100%;6名实验人员对3、4、5、10、20ng/ml浓度的BSP标准品进行测定,结果变异系数在1.96%~6.24%之间,精密度较好;回收率在94.8%~98.7%之间,准确度理想,测量限量为3ng/ml。该试剂盒与人血白蛋白、卵清蛋白等均无交叉反应,对BSA、B-IgG特异性蛋白的检测回收率为101.2%和94.7%;与牛血清白蛋白试剂盒对比测定11种疫苗总计108批,符合率为96.3%,针对不同疫苗,BSP残余量约为BSA的1.12~3.13倍,验证结果表明,该试剂盒可检测疫苗中BSP而不仅是BSA,能更全面客观地反映疫苗中牛血清的真实情况,有利于疫苗生产的严格质量监控。     

潍坊市健康人群麻疹、风疹、流行性腮腺炎抗体水平调查

目的了解潍坊市健康人群麻疹、风疹、流行性腮腺炎血清抗体水平,为消除麻疹、控制风疹及腮腺炎疫情提供依据。方法 2011年8月,采集昌乐、潍城2个县区<2、2～5、5～8、8～11、11～15、15～20、20～40、>40岁健康人群血标本,应用酶联免疫吸附试验检测麻疹、风疹、腮腺炎IgG抗体。结果检测总数320人,其中昌乐县健康人群的麻疹抗体阳性率为98.75%、潍城为96.25%;风疹抗体阳性率昌乐县健康人群为89.38%、潍城区为91.88%。昌乐、潍城两地区健康人群麻疹、风疹的抗体阳性率差异均无统计学意义(χ2=1.15、0.59,P>0.05);昌乐县健康人群腮腺炎抗体阳性率为84.38%、潍城区健康人群为66.25%,两者差异有统计学意义(χ2=14.14,P<0.01);8组不同年龄健康人群的麻疹抗体阳性率为92.50%～100%,风疹抗体阳性率为87.50%～92.50%,腮腺炎抗体阳性率为67.50%～85.00%,各年龄组间均无统计学意义(χ2=13.49、1.58、5.23,P>0.05)。结论潍坊市麻疹抗体阳性率较高,风疹、腮腺炎抗体阳性率相对偏低,今后须要积极开展学龄儿童麻腮风三联疫苗的查漏补种工作。     

冻干水痘活疫苗的研制

Oka株水痘病毒是唯一被WHO椎荐用于生产水痘活疫苗的减毒株,1974年由日本大呢大学微生物病研究会（BIKEN）高桥博士培养成功的【人1996年从BIKEN引进o财株病毒,MRC－5人H倍体细胞在本所进行水造活疫苗研制。1材料与方法1．1细胞株24代MRC－5人H倍体细胞由BIKEN提供1．2病毒株BIKEN提供的Oka病毒减毒株母种子,批号为M2001。1．3水疡病毒标准抗血清BIKEN提供批号OAKK39－4,中和抗体滴度为1：74o000豆．4培养液细胞培养液为9％股牛血清的MEM液,维持液为3％股牛血清MEM液,疫苗液为5％蔗糖,O．5％明胶,0．1％谷氨酸…     

S79株腮腺炎病毒制备纯化抗原用于诊断试剂的研究

以S79株腮腺炎病毒制备纯抗原,用于制备检测腮腺炎抗体(IgG)的ELISA试剂盒。将腮腺炎病毒S79株培养液用中空纤维超滤器进行浓缩,经PEG沉淀后,采用蔗糖密度梯度离心法纯化抗原;以纯化的S79株腮腺炎病毒为包被抗原,制备成ELISA腮腺炎病毒抗体(IgG)诊断试剂,并与SIGMA同类产品进行比较。结果显示,经纯化的S79株抗原的比活力为412.9HAU/mg,杂蛋白清除率为99.5%。应用纯化的S79株腮腺炎病毒抗原制备的ELISA试剂,与SIGMA试剂比较,敏感度为94.4%,特异度为91.7%,一致性为93.3%。结论,以纯化的S79株腮腺炎病毒为包被抗原,可用于大批量ELISA腮腺炎抗体诊断试剂盒的制备。     

2020年广州市荔湾区健康人群麻疹、风疹和水痘的IgG抗体水平监测分析

目的了解广州市荔湾区2020年健康人群的麻疹、风疹和水痘IgG抗体水平,为本地制定免疫规划策略提供科学依据。方法采用分层随机抽样方法确定被调查对象,采集血液标本共238份,进行麻疹、风疹和水痘的IgG抗体水平监测并进行分析。结果 ELISA检测血清样本共238份,麻疹、风疹和水痘IgG抗体阳性率分别为97.06%、92.02%和79.41%,抗体几何平均浓度(geometric mean concentration, GMC)分别为1 204.65、43.38和290.38 mIU/mL。男女性别比为1.02∶1,麻疹、风疹和水痘IgG抗体阳性率差异无统计学意义(P0.05)。2～4岁组麻疹IgG阳性率最低,不同年龄组阳性率差异有统计学意义(χ~2=48.158,P0.05);0～1岁组的风疹IgG抗体阳性率最低,不同年龄组抗体阳性率差异有统计学意义(χ~2=36.980,P0.05);0～1岁组水痘IgG抗体阳性率非常低,不同年龄组抗体阳性率差异有统计学意义(χ~2=30.832,P0.05)。接种麻疹疫苗≥2剂次的人群IgG抗体阳性率为95.10%,不同免疫史差异无统计学意义(P=0.448,P0.05);接种风疹疫苗0剂次的人群IgG抗体阳性率最低,不同免疫史差异无统计学意义(P=0.020,P0.05);接种水痘减毒活疫苗0剂次的人群IgG抗体阳性率最低,接种2剂次的阳性率最高,不同免疫史差异有统计学意义(P=0.010,P0.05)。结论本区麻疹、风疹IgG抗体均维持在较高水平并有所提高;水痘IgG抗体水平较低,存在暴发、流行的可能。应加强麻疹、风疹免疫接种和查漏补种工作;有针对性地宣传水痘减毒活疫苗并推广接种;还须积极开展麻疹、风疹和水痘IgG抗体水平监测。     

精制地鼠肾细胞狂犬病疫苗纯化工艺的建立

分别用Srpharose4B、Sephacryl-200HR和Sepharose6-Fastflow柱色谱进行地鼠肾细胞狂犬病疫苗浓缩原液纯化试验,试制精制地鼠肾细胞狂犬病疫苗.对疫苗的残余牛血清含量、效力、收获率和安全性进行检测,优化和建立了精制地鼠肾细胞狂犬病疫苗纯化工艺.     

粗制地鼠肾细胞狂犬病疫苗纯化工艺的建立

分别用Sepharose 4B、Sephacryl-200HR和Sepharose6-Fast flow柱色谱进行地鼠肾细胞狂犬疫苗浓缩原液纯化试验,试制精制地鼠肾细胞狂犬病疫苗。对疫苗的残余牛血清含量、效力、收获率和安全性进行检测,优化和建立了精制地鼠肾细胞狂犬病疫苗纯化工艺。     

疫苗

<正> 考虑了用鸡细胞生产人病毒疫苗问题。使用30个11日龄Spafas Cofal种的无马立克病毒的有胚鸡蛋的鸡胚为原始细胞悬液,并使用Cutodex3微载体。培基中含胎牛血清,或胎牛血清、鸡血清和tryptose pho-sphate肉汤,以及组织培养瓶或     

2016年吉林省健康从业人员麻疹和风疹抗体水平调查分析

目的调查分析吉林省2016年健康从业人员的麻疹(measles)和风疹(rubella)的抗体水平。方法采用方便抽样的方法,采集吉林省2016年各地区18岁及以上健康从业人员1 419人的血清,检测其麻疹和风疹的IgG抗体,进行描述性分析。结果 2016年吉林省健康从业人员麻疹IgG抗体阳性率为91.26%,风疹IgG抗体阳性率为81.46%。麻疹和风疹报告病例的时间分布,主要流行季节均在春季。吉林省8个地市麻疹IgG抗体阳性率在82.00%～98.00%之间,差异有统计学意义(χ~2=35.59,P<0.05);风疹IgG抗体阳性率在63.75%～86.24%,差异有统计学意义(χ~2=37.49,P<0.05)。男性与女性麻疹IgG抗体阳性率分别为92.64%和90.70%,性别差异无统计学意义(χ~2=1.38、P=1.42,P>0.05);男性与女性的风疹IgG抗体阳性率分别为82.84%和80.91%,性别差异无统计学意义(χ~2=0.72,P=0.22,P>0.05)。各年龄组麻疹IgG抗体阳性率在88.73%～100.00%之间,年龄差异无统计学意义(χ~2=7.11、P=0.21,P>0.05);风疹IgG抗体阳性率在75.00%～88.89%之间,年龄差异无统计学意义(χ~2=11.24、P=0.47,P>0.05)。结论 2016年吉林省健康从业人员麻疹和风疹的IgG抗体阳性率未达到可形成免疫屏障的水平,建议对该人群开展麻疹和风疹疫苗加强免疫。     

Studies on live rubella vaccine. V. Quantitative aspects of interference between rubella, measles and mumps viruses in their trivalent vaccine

Rubella vaccine combined with measles and mumps vaccines was administered in a single injection to children of 1 to 5 years of age. All three vaccines were serologically effective, and the clinical reactions caused by measles vaccine were considerably alleviated, when 6 x 10(3) PFU of rubella and 10(4) TCD50 per dose of mumps vaccines were combined with 5 x 10(4) TCD50 of measles vaccine. When a larger amount of mumps vaccine (3 x 10(5) TCD50/dose) was used, it caused interference with the rubella and measles viruses, i.e., the antibody response to rubella virus became poor and the incidence of clinical reactions to measles virus decreased. On the other hand, when 5 x 10(5) TCD50/dose of measles vaccine was combined with 10(4) TCD50/dose of mumps vaccine, the clinical reactions to measles virus were decreased but were almost the same as those induced by this vaccine alone.     

Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay.

The quantitative PCR infectivity assay is a combination of virus propagation and quantitative PCR. Previously [Schalk JAC, van den Elzen C, Ovelgonne H, Baas C, Jongen PMJM. Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real-time PCR. J Virol Methods 2004;117:179-87.], we used this assay to estimate the titer of infectious measles virus in trivalent, live, measles, mumps, rubella vaccines (MMR). Here we describe the further improvement and development of the assay for simultaneous potency estimation of measles, mumps and rubella viruses. The potency of measles and mumps virus is estimated within one assay after 1 day of cell culture. The potency of rubella virus is estimated in a separate assay after 2 days of cell culture. Compared to conventional CCID50 and plaque assays, the quantitative PCR infectivity assay has the advantage in being fast because the assay is not dependent on the formation of cytopathic effect. Furthermore assay design is simplified: serological neutralization can be omitted because PCR is virus-specific and, under the conditions used, the individual components of trivalent measles, mumps, rubella vaccines do not interfere with each other. The assay was validated and compared to the performance of a plaque assay.     

A comparison of an enzyme-linked immunosorbent assay and counter current electrophoresis for the detection of bovine serum albumin in virus vaccines

A monoclonal antibody directed against bovine serum albumin (BSA) has been developed and used in an enzyme-linked immunosorbent assay (ELISA) system for the detection of BSA in virus vaccines. The results correlated well with those obtained with a counter current electrophoresis system which has been employed routinely for this purpose. The ELISA was slightly more sensitive and more readily applicable to the screening of large numbers of samples but could not be used in the presence of certain stabilizers.     

Avidity of immunoglobulin G to rubella virus in post-vaccination and post-infection immunity

Comparative evaluation of avidity of IgG to rubella virus in vaccinated persons, in patients with rubella or other exanthematous illness, and in healthy persons revealed similar patterns in post-vaccination and post-infection immunity. Virus specific low avidity IgG (index of avidity < or =30%) were detected in patients with rubella during 7 weeks after symptoms appeared as well as in vaccinated persons which were tested 6 weeks after vaccination. Low avidity antibodies in sera were detected in 96% of patients with rubella and in 75% of vaccinated persons which were not immune before immunization. Live attenuated vaccines Ervevax, Priorix, and MMR-II had similar ability to induce low avidity IgG to rubella virus. Increase of low avidity antibodies concentration was noted after immunization of children with low levels of antibodies before vaccination. After immunization of persons with high avidity antibodies in serum, index of avidity remained above threshold. Anamnestic high avidity IgG (index of avidity 51-100%) were detected in majority of immune healthy persons (96.4%) as well as in patients with exanthematous illnesses not related to rubella infection (93.6%). ELISA test-systems for detection of low avidity IgG to rubella virus allow to obtain reliable information about seroconversion rate and characteristics of immune response in vaccines. Detection of low avidity IgG in serum obtained 5-6 weeks after immunization points to primary immune response, whereas identification of high avidity antibodies reveals already immune persons.     

Immunogenic activity of temperature sensitive mutation of herpes simplex virus type-1 in mono- and polyvalent conditions with different attenuated strains of virus. II. Analysis of humoral immunologic response induced by mutants of temperature sensitive herpes simplex type-1 virus in polyvalent systems

The ability of mutant ts HSV-1 on 45 passage to induction of IgG antibody response in the presence of other attenuated viral strain, like measles, mumps, rubella was evaluated, and the effect of mutant ts HSV-1 on humoral immunity induced by attenuated measles and mumps strains was also tested. The obtained results clearly indicated that even immunization with other RNA virus strains had no effect on IgG antibody response to mutant ts HSV-1. Significant differences were observed in IgG antibody responses to mumps and measles between groups of guinea pigs immunized with these viruses alone or together with other viruses. This was especially observed in the case of mumps virus. It clearly shows that change of virus concentration rates in polyvalent schema of immunization is needed.     

国产腮腺炎和进口麻风腮疫苗免后腮腺炎HI抗体比较

报道了用国产流行腮腺炎减毒活疫苗和美国产麻－风－腮减毒活疫苗接种８～９岁小学生后,采血进行ＨＩ抗体测定比较,其抗体阳转率均在８０％左右,ＧＭＴ为７．３５～１０．０３,说明两种疫苗均有较好的免疫应答     

Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response

A trivalent measles-mumps-rubella live virus vaccine, containing measles AIK-C strain, mumps Hoshino strain, and rubella Takahashi strain, was evaluated in 229 children, aged 1 to 5 years. The vaccine induced a high seroconversion rate: 221 (98.7%) out of 224 subjects initially seronegative for measles virus, 167 (93.3%) out of 179 initially seronegative for mumps virus, and 212 (99.1%) out of 214 initially seronegative for rubella virus. It also induced a sufficient cellular immunity against each of the three viruses in over 90% of the subjects, as judged by virus-specific interferon-gamma (IFN-gamma) production. Virus-specific IFN-gamma production was observed 10 days after vaccination by stimulation with measles virus and rubella virus and 14 days after vaccination by stimulation with mumps virus. Mumps-virus-specific IFN-gamma production was observed in 7 out of 12 recipients without seroconversion for mumps virus. And measles-virus-specific IFN-gamma production was demonstrated in one out of three recipients without seroconversion for measles virus. A significant correlation was observed between the serum antibody and IFN-gamma production six weeks after vaccination for measles virus (r = 0.201, P less than 0.01) and for mumps virus (r = 0.174, P less than 0.05) but not for rubella virus (r = -0.045, P less than 0.05). The incidence of febrile reactions of greater than or equal to 37.5 C was quite low, 14.4%, and that of greater than or equal to 39 C occurred in only 1.3% of the recipients. These results suggested that the trivalent vaccine induced sufficient humoral and cellular immunity and yet resulted in no more untoward reaction than observed from the measles vaccine alone.